Literature DB >> 10397275

The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and down-regulates their Fas-receptor expression.

D Coppola1, B Saunders, L Fu, W Mao, S V Nicosia.   

Abstract

Cell proliferation and papillogenesis are growth factor-sensitive events in the ovarian mesothelium, the tissue source of ovarian epithelial cancer. To further investigate the regulation of cell proliferation in this tissue, rabbit ovarian mesothelial cells (OMC) were transfected in vitro with a CVN expression vector carrying the human gene for insulin-like growth factor 1 receptor (IGF-1R). The growth characteristics of IGF-1R transfectants (OMIR) and their response to IGF-1 were then compared with those of OMC in serumless HL-1 cultures. OMIR cells formed epithelial-like colonies and, even when nonconfluent, produced tridimensional structures reminiscent of papillae seen in ovarian serous epithelial tumors. After 3 and 7 days of exposure to IGF-1, OMIR cells grew approximately 20-fold (P < 0.05), and papillogenesis was 15- to 25-fold over similar events in OMC, respectively. Exposure to treatment with antisense oligonucleotides against IGF-1R mRNA inhibited OMIR growth rate by 70%. Western immunoblotting and flow cytometry revealed higher expression of IGF-1R in OMIR cells than in OMC. The reverse was true when Fas-receptor expression was evaluated. OMIR cells were clonogenic in 15% serum-rich soft agar assay (OMIR:OMC colony-forming ratio 150-200:1), and tumorigenic in nude mice in which high-grade carcinomas with occasional lung metastases were observed. These data suggest that IGF-1R plays a role in ovarian epithelial carcinogenesis. The overexpression of this receptor induces transformation and morphogenesis of OMCs via an autocrine mechanism. IGF-1R may down-regulate the Fas expression rendering transformed ovarian mesothelial cells resistant to apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397275

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

Review 1.  Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology.

Authors:  Lynn C Shaw; Maria B Grant
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

2.  Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.

Authors:  Deeksha Vishwamitra; Ping Shi; Desiree Wilson; Roxsan Manshouri; Francisco Vega; Ellen J Schlette; Hesham M Amin
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

3.  Xenograft and Transgenic Mouse Models of Epithelial Ovarian Cancer and Non Invasive Imaging Modalities to Monitor Ovarian Tumor Growth In situ -Applications in Evaluating Novel Therapeutic Agents.

Authors:  Denise C Connolly; Harvey H Hensley
Journal:  Curr Protoc Pharmacol       Date:  2009-06-01

Review 4.  Current status on biologic therapies in the treatment of epithelial ovarian cancer.

Authors:  Ernest S Han; Paul Lin; Mark Wakabayashi
Journal:  Curr Treat Options Oncol       Date:  2009-04-21

5.  miR-494 suppresses tumor growth of epithelial ovarian carcinoma by targeting IGF1R.

Authors:  Na Li; Xiaosu Zhao; Lufei Wang; Shi Zhang; Manhua Cui; Jin He
Journal:  Tumour Biol       Date:  2015-12-22

Review 6.  Calcium Intake and the Risk of Ovarian Cancer: A Meta-Analysis.

Authors:  Xingxing Song; Zongyao Li; Xinqiang Ji; Dongfeng Zhang
Journal:  Nutrients       Date:  2017-06-30       Impact factor: 5.717

7.  Association Between Pre-diagnostic Dietary Supplements Intake and Ovarian Cancer Survival: Findings From a Prospective Cohort Study in Chinese Women.

Authors:  Jia-Hui Gu; Ting-Ting Gong; Qi-Jun Wu; Fang-Hua Liu; Zhao-Yan Wen; Chang Gao; Yi-Fan Wei; Zhuo Yang
Journal:  Front Nutr       Date:  2021-12-14

8.  PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma.

Authors:  Jacob Thomsen; Rikke Hjortebjerg; Ulrick Espelund; Gitte Ørtoft; Poul Vestergaard; Nils E Magnusson; Cheryl A Conover; Trine Tramm; Henrik Hager; Claus Høgdall; Estrid Høgdall; Claus Oxvig; Jan Frystyk
Journal:  Oncotarget       Date:  2015-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.